Brokerages Set Organon & Co. (NYSE:OGN) PT at $11.40

Organon & Co. (NYSE:OGN) has been given a consensus recommendation of “Reduce” by the seven brokerages that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $11.40.

Several equities analysts have recently issued reports on the stock. BNP Paribas Exane reissued a “neutral” rating and issued a $14.00 price target (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Weiss Ratings upgraded Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Finally, Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their target price for the company from $5.00 to $14.00 in a research note on Tuesday, April 28th.

Organon & Co. Trading Up 0.2%

Organon & Co. stock traded up $0.03 during midday trading on Friday, hitting $13.52. 3,023,720 shares of the stock were exchanged, compared to its average volume of 2,256,990. The company has a fifty day simple moving average of $13.43 and a two-hundred day simple moving average of $9.76. Organon & Co. has a 52 week low of $5.69 and a 52 week high of $13.60. The stock has a market capitalization of $3.55 billion, a PE ratio of 14.53, a P/E/G ratio of 1.25 and a beta of 1.54. The company has a quick ratio of 1.42, a current ratio of 1.97 and a debt-to-equity ratio of 9.47.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.49 billion. Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.02 EPS. Equities research analysts anticipate that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Monday, May 11th were issued a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Monday, May 11th. Organon & Co.’s payout ratio is 8.60%.

Insider Activity

In other Organon & Co. news, SVP Lynette Holzbaur bought 26,448 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was acquired at an average cost of $13.35 per share, with a total value of $353,080.80. Following the purchase, the senior vice president owned 52,851 shares in the company, valued at $705,560.85. This trade represents a 100.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.62% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC increased its holdings in Organon & Co. by 105.2% during the 4th quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock worth $61,282,000 after purchasing an additional 4,394,814 shares in the last quarter. UBS Group AG lifted its holdings in shares of Organon & Co. by 55.2% in the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after purchasing an additional 1,527,492 shares in the last quarter. First Trust Advisors LP boosted its position in shares of Organon & Co. by 78.1% during the first quarter. First Trust Advisors LP now owns 3,227,320 shares of the company’s stock worth $19,332,000 after buying an additional 1,415,239 shares during the period. Private Management Group Inc. boosted its position in shares of Organon & Co. by 38.3% during the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock worth $31,169,000 after buying an additional 1,204,979 shares during the period. Finally, Balyasny Asset Management L.P. grew its holdings in shares of Organon & Co. by 102.1% during the third quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company’s stock worth $23,925,000 after buying an additional 1,131,941 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.